Obinutuzumab for Membranous Nephropathy: Patient-Level Systematic Review

İlker Atay's dataset contains case-level extraction analysis from a systematic review of 89 patients across 19 publications, evaluating obinutuzumab treatment for PLA2R-associated membranous nephropathy. The data includes patient outcomes such as clinical and immunological remission rates, prior treatment responsiveness, and follow-up duration. It synthesizes findings from MEDLINE, Web of Science, SCOPUS, and grey literature to characterize response patterns and influencing factors.

Use Cases

• Analyzing remission rate differences between patients refractory to prior therapy and prior responders based on reported patient outcomes.
• Investigating the relationship between follow-up duration and clinical remission rates using the 12-month median follow-up data.
• Assessing geographic variation in reported treatment outcomes, as most patients (64%) were reported from China.
• Synthesizing evidence on adverse event profiles for obinutuzumab in this condition, noting reporting was inconsistent.

Strengths

• Includes data from 89 individual patients, providing a detailed case-level perspective.
• Systematically sourced from 19 publications across multiple databases (MEDLINE, Web of Science, SCOPUS, grey literature).
• Licensed under CC-BY-4.0, permitting broad reuse with attribution.

Limitations

• Column names and specific data structure are not provided, limiting immediate analytical utility.
• Adverse events were inconsistently reported across the source studies.
• Reported outcomes show geographic variation and may be influenced by differences in follow-up duration and publication type.

Provenance

Source

İlker Atay

Collection Method

Systematic review and case-level extraction analysis from published case reports and case series.

Freshness

Last updated 2026-03-19.

Geography

Global, with a majority (64%) of patients reported from China.